SAN DIEGO, March 11, 2021 / PRNewswire / -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory

SAN DIEGO, March 4, 2021 / PRNewswire / -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory

- PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn's disease - - PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision medicine approach - SAN DIEGO, March 3, 2021 /

SAN DIEGO, Feb. 16, 2021 / PRNewswire / -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory

- PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn's disease - - PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision medicine approach - SAN DIEGO, Dec.

- New investors include Eventide, RTW, Perceptive Advisors, Cormorant Capital, Cowen Healthcare Investments and Point72 - -Proceeds to accelerate clinical development of PRA023, a potential best in class TL1A antibody for IBD, and expansion of Promtheus' 360 platform - SAN DIEGO, Nov.

SAN DIEGO, September 29, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of

SAN DIEGO, Aug. 25, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with Inflammatory

-Prometheus to receive an upfront payment and payments upon achievement of several milestones expected within the next 12 months– -Falk to pay 25% of global development costs of IBD program- -Falk to leverage the Prometheus 360™ platform to create next-generation IBD precision medicines- SAN DIEGO

SAN DIEGO, August 4, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with Inflammatory